These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. MYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes. Rekhi B; Upadhyay P; Ramteke MP; Dutt A Mod Pathol; 2016 Dec; 29(12):1532-1540. PubMed ID: 27562493 [TBL] [Abstract][Full Text] [Related]
7. MYOD1 as a prognostic indicator in rhabdomyosarcoma. Ahmed AA; Habeebu S; Farooqi MS; Gamis AS; Gonzalez E; Flatt T; Sherman A; Surrey L; Arnold MA; Conces M; Koo S; Dioufa N; Barr FG; Tsokos MG Pediatr Blood Cancer; 2021 Sep; 68(9):e29085. PubMed ID: 33913590 [TBL] [Abstract][Full Text] [Related]
8. Recurrent SRF-RELA Fusions Define a Novel Subset of Cellular Myofibroma/Myopericytoma: A Potential Diagnostic Pitfall With Sarcomas With Myogenic Differentiation. Antonescu CR; Sung YS; Zhang L; Agaram NP; Fletcher CD Am J Surg Pathol; 2017 May; 41(5):677-684. PubMed ID: 28248815 [TBL] [Abstract][Full Text] [Related]
9. Establishment and Characterization of a Cell Line (S-RMS1) Derived from an Infantile Spindle Cell Rhabdomyosarcoma with Colletti M; Galardi A; Miele E; Di Paolo V; Russo I; De Stefanis C; De Vito R; Rinelli M; Ciolfi A; De Angelis B; Zin A; Guffanti A; Digilio MC; Novelli A; Alaggio R; Milano GM; Di Giannatale A Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34067464 [No Abstract] [Full Text] [Related]
10. Expanding the Spectrum of Intraosseous Rhabdomyosarcoma: Correlation Between 2 Distinct Gene Fusions and Phenotype. Agaram NP; Zhang L; Sung YS; Cavalcanti MS; Torrence D; Wexler L; Francis G; Sommerville S; Swanson D; Dickson BC; Suurmeijer AJH; Williamson R; Antonescu CR Am J Surg Pathol; 2019 May; 43(5):695-702. PubMed ID: 30720533 [TBL] [Abstract][Full Text] [Related]
11. Spindle Cell/Sclerosing Rhabdomyosarcoma With Rakheja D; Park JY; Alhasan M; Uddin N Int J Surg Pathol; 2022 Dec; 30(8):950-955. PubMed ID: 35466752 [TBL] [Abstract][Full Text] [Related]
12. [Spindle cell/sclerosing rhabdomyosarcoma: a clinicopathological study of 20 cases]. Yang L; Zhang HJ; Yang SJ Zhonghua Bing Li Xue Za Zhi; 2020 Apr; 49(4):336-342. PubMed ID: 32268670 [No Abstract] [Full Text] [Related]
13. Infantile Rhabdomyosarcomas With VGLL2 Rearrangement Are Not Always an Indolent Disease: A Study of 4 Aggressive Cases With Clinical, Pathologic, Molecular, and Radiologic Findings. Cyrta J; Gauthier A; Karanian M; Vieira AF; Cardoen L; Jehanno N; Bouvet M; Bouvier C; Komuta M; Le Loarer F; Orbach D; Rome A; Minard-Colin V; Brichard B; Pluchart C; Thebaud E; Renard M; Pannier S; Brisse H; Petit P; Benoist C; Schleiermacher G; Geoerger B; Vincent-Salomon A; Fréneaux P; Pierron G Am J Surg Pathol; 2021 Jun; 45(6):854-867. PubMed ID: 33949344 [TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic features and molecular spectrum of spindle cell and sclerosing rhabdomyosarcomas in the head and neck region. Wang Y; Li J; Tian Z; Zhu Y Int J Clin Exp Pathol; 2018; 11(7):3436-3444. PubMed ID: 31949721 [TBL] [Abstract][Full Text] [Related]
15. A clinicopathologic study of head and neck rhabdomyosarcomas showing FOXO1 fusion-positive alveolar and MYOD1-mutant sclerosing are associated with unfavorable outcome. Owosho AA; Huang SC; Chen S; Kashikar S; Estilo CL; Wolden SL; Wexler LH; Huryn JM; Antonescu CR Oral Oncol; 2016 Oct; 61():89-97. PubMed ID: 27688110 [TBL] [Abstract][Full Text] [Related]
16. The expanding morphological and genetic spectrum of MYOD1-mutant spindle cell/sclerosing rhabdomyosarcomas: a clinicopathological and molecular comparison of mutated and non-mutated cases. Tsai JW; ChangChien YC; Lee JC; Kao YC; Li WS; Liang CW; Liao IC; Chang YM; Wang JC; Tsao CF; Yu SC; Huang HY Histopathology; 2019 May; 74(6):933-943. PubMed ID: 30604891 [TBL] [Abstract][Full Text] [Related]
17. Molecular diagnostics in the management of rhabdomyosarcoma. Arnold MA; Barr FG Expert Rev Mol Diagn; 2017 Feb; 17(2):189-194. PubMed ID: 28058850 [TBL] [Abstract][Full Text] [Related]
18. Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype. Heerema-McKenney A; Wijnaendts LC; Pulliam JF; Lopez-Terrada D; McKenney JK; Zhu S; Montgomery K; Mitchell J; Marinelli RJ; Hart AA; van de Rijn M; Linn SC Am J Surg Pathol; 2008 Oct; 32(10):1513-22. PubMed ID: 18708938 [TBL] [Abstract][Full Text] [Related]
19. Integrative clinical and biopathology analyses to understand the clinical heterogeneity of infantile rhabdomyosarcoma: A report from the French MMT committee. Butel T; Karanian M; Pierron G; Orbach D; Ranchere D; Cozic N; Galmiche L; Coulomb A; Corradini N; Lacour B; Proust S; Guerin F; Boutroux H; Rome A; Mansuy L; Vérité C; Defachelles AS; Tirode F; Minard-Colin V Cancer Med; 2020 Apr; 9(8):2698-2709. PubMed ID: 32087612 [TBL] [Abstract][Full Text] [Related]
20. [Congenital spindle cell/sclerosing rhabdomyosarcoma: a clinicopathological analysis]. Xu JT; Fu LB; Yao XF; Jia C; Guan XX; Zhang M; He LJ Zhonghua Bing Li Xue Za Zhi; 2024 Apr; 53(4):344-350. PubMed ID: 38556817 [No Abstract] [Full Text] [Related] [Next] [New Search]